Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The bisphosphonates, risks and benefits of long term use

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Role of the purinergic P2X receptors in osteoclast pathophysiology

    Research output: Contribution to journalReviewResearchpeer-review

  1. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Over- and Under-Treatment of Hypothyroidism Is Associated with Excess Mortality: A Register-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Women's lived experiences of learning to live with osteoporosis: a longitudinal qualitative study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Bisphosphonates are widely used globally as the main treatment for osteoporosis. Both safety and efficacy have only been rigorously evaluated in studies of relatively short duration (3-5 years), with smaller extension studies. The evidence for benefit beyond five years in intervention studies is limited and does not include proven efficacy against nonvertebral fractures. Observational studies suggest a sustained benefit against hip fractures. Bisphosphonates are stored in the skeleton for months to years, depending on the degree of bone turnover and the binding properties of the bisphosphonate in question. The effects of continued treatment on bone strength is not known but there are concerns that osteonecrosis of the jaw and atypical femur fractures may stem from long term bisphosphonate use.
Original languageEnglish
JournalCurrent Opinion in Pharmacology
Volume13
Issue number3
Pages (from-to)435-9
Number of pages5
ISSN1471-4892
DOIs
Publication statusPublished - Jun 2013

ID: 38706660